187 related articles for article (PubMed ID: 19169844)
1. Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease.
Auray-Blais C; Millington DS; Young SP; Clarke JT; Schiffmann R
J Inherit Metab Dis; 2009 Apr; 32(2):303-8. PubMed ID: 19169844
[TBL] [Abstract][Full Text] [Related]
2. Neurological complications of Anderson-Fabry disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Arnao V; Licata G; Pinto A
Curr Pharm Des; 2013; 19(33):6014-30. PubMed ID: 23448452
[TBL] [Abstract][Full Text] [Related]
3. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
5. [Fabry disease from the neurologist's point of view: is it a rare cause of strokes?].
Marti-Martinez S; Climent V; Pampliega-Perez A; Martin-Estefania C; Leiva-Santana C
Rev Neurol; 2015 Jan; 60(2):93-5. PubMed ID: 25583594
[No Abstract] [Full Text] [Related]
6. Biomarkers of Fabry disease nephropathy.
Schiffmann R; Waldek S; Benigni A; Auray-Blais C
Clin J Am Soc Nephrol; 2010 Feb; 5(2):360-4. PubMed ID: 19965549
[TBL] [Abstract][Full Text] [Related]
7. High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb
Auray-Blais C; Lavoie P; Boutin M; Abaoui M
Curr Protoc Hum Genet; 2017 Apr; 93():17.26.1-17.26.12. PubMed ID: 28384397
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry.
Kitagawa T; Ishige N; Suzuki K; Owada M; Ohashi T; Kobayashi M; Eto Y; Tanaka A; Mills K; Winchester B; Keutzer J
Mol Genet Metab; 2005 Jul; 85(3):196-202. PubMed ID: 15979031
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
[TBL] [Abstract][Full Text] [Related]
10. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.
Vedder AC; Linthorst GE; van Breemen MJ; Groener JE; Bemelman FJ; Strijland A; Mannens MM; Aerts JM; Hollak CE
J Inherit Metab Dis; 2007 Feb; 30(1):68-78. PubMed ID: 17206462
[TBL] [Abstract][Full Text] [Related]
11. High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients.
Auray-Blais C; Lavoie P; Abaoui M; Côté AM; Boutin M; Akbari A; Levin A; Mac-Way F; Tr Clarke J
Clin Chim Acta; 2020 Feb; 501():234-240. PubMed ID: 31778673
[TBL] [Abstract][Full Text] [Related]
12. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease.
Auray-Blais C; Cyr D; Mills K; Giguère R; Drouin R
J Inherit Metab Dis; 2007 Feb; 30(1):106. PubMed ID: 17171433
[TBL] [Abstract][Full Text] [Related]
13. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
[No Abstract] [Full Text] [Related]
14. [The neurological manifestations of Fabry disease. A review].
Firsov KV; Kotov AS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
[TBL] [Abstract][Full Text] [Related]
15. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R
Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222
[TBL] [Abstract][Full Text] [Related]
16. What lies beneath: Fabry nephropathy in a female patient with severe cerebrovascular disease.
Romão EA; Lourenço CM; Júnior WM; Rolfs A; Muñoz V; Vieira Neto OM; Dantas M; Silva GE; Costa RS
Clin Nephrol; 2013 Apr; 79(4):330-4. PubMed ID: 23537685
[TBL] [Abstract][Full Text] [Related]
17. [Fabry disease in cardiology: Diagnosis and therapeutic approaches].
Çavuşoğlu Y; Özpelit E; Arslan N; Demir M; Kahveci G; Onay H; Ökçün EÖB; Tufekcioglu O; Tülüce SY; Yıldırım GK
Turk Kardiyol Dern Ars; 2020 Dec; 48(Suppl 2):1-42. PubMed ID: 33476309
[TBL] [Abstract][Full Text] [Related]
18. Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease.
Chien YH; Olivova P; Zhang XK; Chiang SC; Lee NC; Keutzer J; Hwu WL
Mol Genet Metab; 2011 Jan; 102(1):57-60. PubMed ID: 20864368
[TBL] [Abstract][Full Text] [Related]
19. Renal complications of Fabry disease in children.
Najafian B; Mauer M; Hopkin RJ; Svarstad E
Pediatr Nephrol; 2013 May; 28(5):679-87. PubMed ID: 22898981
[TBL] [Abstract][Full Text] [Related]
20. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.
Nakao S; Kodama C; Takenaka T; Tanaka A; Yasumoto Y; Yoshida A; Kanzaki T; Enriquez AL; Eng CM; Tanaka H; Tei C; Desnick RJ
Kidney Int; 2003 Sep; 64(3):801-7. PubMed ID: 12911529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
